Other News To Note

• Karus Therapeutics Ltd., of Southhampton, UK, entered a collaboration with the Babraham Institute, of Cambridge, UK, to further characterize treatments for inflammatory diseases through the regulation of phosphatidylinositol-3-kinase (PI3K) – a family of enzymes important to immune cell function.